LLY vs NBIX: fair value comparison
Eli Lilly and Company and Neurocrine Biosciences, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LLY currently sits closer to the top of our discount ranking. NBIX carries the stronger quality grade.
| LLY | NBIX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $1,115.70 | $156.76 |
| 12-month range | $862.86–$1,160.00 | $131.78–$167.77 |
| Sector rank | #14 of 113 Healthcare | #17 of 113 Healthcare |
| Quality grade | B | A |
| Leverage | High | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: LLY fair value analysis · NBIX fair value analysis